Intento Releases 9th Annual "State of Translation Automation 2025" Industry Report
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Intento has released its 9th annual industry report, The State of Translation Automation 2025 (formerly State of Machine Translation). The report analyzes the latest advances in translation automation and...
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally...
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
HONG KONG, Feb. 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its...
MoEngage's Email Benchmarks Report Reveals a Shift in Personalization Trends for 2025
Analysis of 17.3 billion marketing emails reveals behavior-based emails can achieve up to 300.7x conversion rates compared to non-personalized emails SAN FRANCISCO, Jan. 15, 2025 /PRNewswire/ -- MoEngage, an insights-led cross-channel customer...